Showing results (61-70 of 212) with videos related to

Sort By:
Pageof 22
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2008
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockadeMarcella Fassò, Rebecca Waitz, Yafei Hou, et al.
Cancer Immunology Research|September 24, 2020
Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-TLi Zhang, Harini Kandadi, Hai Yang, et al.
The Journal of Clinical Investigation|July 16, 2009
An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humansYafei Hou, Jason DeVoss, Vinh Dao, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 2012
Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patientsSerena S Kwek, Vinh Dao, Ritu Roy, et al.
Cancer Immunology, Immunotherapy : CII|January 9, 2021
Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patientsElliot Naidus, Jerome Bouquet, David Y Oh, et al.
American Journal of Translational Research|August 27, 2013
Chemotaxis of human induced pluripotent stem cell-derived endothelial cellsNgan F Huang, Ruby E Dewi, Janet Okogbaa, et al.
Cancer Immunology, Immunotherapy : CII|February 9, 2010
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphataseBrian M Olson, Thomas P Frye, Laura E Johnson, et al.
Pageof 22